U.S. Capital Markets Stock News

NasdaqCM:MBCN
NasdaqCM:MBCNBanks

Middlefield Banc (MBCN) Q4 EPS Drop Tests Bullish Earnings Momentum Narrative

Middlefield Banc FY 2025 headline results Middlefield Banc (MBCN) has wrapped up FY 2025 with fourth quarter revenue of US$19.8 million and basic EPS of US$0.39, rounding out a trailing twelve month run of US$77.6 million in revenue and EPS of US$2.39. Over that period, quarterly revenue has moved from US$17.6 million in Q4 2024 to the latest US$19.8 million print, while basic EPS has shifted from US$0.60 to US$0.39, giving investors a clear view of how the income line has tracked against the...
NasdaqGS:AAPL
NasdaqGS:AAPLTech

How Strong Q1 2026 Results And Google AI Tie‑Up At Apple (AAPL) Has Changed Its Investment Story

In recent days, Apple reported first‑quarter 2026 results showing revenue of US$143.76 billion and net income of US$42.10 billion, alongside a US$0.26 per‑share dividend and completion of a roughly US$25.20 billion share buyback tranche. At the same time, Apple outlined a broader push into more affordable hardware and AI‑enhanced services, including a low‑cost MacBook and a Gemini‑powered Siri upgrade, aimed at deepening ecosystem engagement across new and existing users. Next, we’ll examine...
NasdaqGM:ODD
NasdaqGM:ODDPersonal Products

Assessing Oddity Tech (ODD) Valuation As Cautious Commentary And Credit Amendments Stir Uncertainty

Recent commentary on Oddity Tech (NasdaqGM:ODD) has turned more cautious, as fund updates highlight sector softness and concerns around Il Makiage, while fresh credit facility amendments and a new platform launch add moving parts for investors. See our latest analysis for Oddity Tech. The recent fund commentary and credit facility update come after a tougher stretch for the stock, with a 30 day share price return of 14.4% decline, a 90 day share price return of 24.7% decline and a 1 year...
NYSE:ZBH
NYSE:ZBHMedical Equipment

Zimmer Biomet (ZBH) Margin Compression And One Off Loss Test Bullish Growth Narrative

Zimmer Biomet Holdings (ZBH) has wrapped up FY 2025 with fourth quarter revenue of US$2.2b and basic EPS of US$0.71, alongside trailing twelve month EPS of US$3.56 on revenue of US$8.2b that reflects a net profit margin of 8.6% over the year. The company has seen quarterly revenue range from US$1.9b to US$2.2b through 2025, while basic EPS moved between US$0.71 and US$1.17, giving investors a clear view of how earnings tracked across the year against that full year margin outcome. With...